Back to top
more

Cempra, Inc. (CEMP)

(Delayed Data from NSDQ)

$2.33 USD

2.33
511,620

+0.03 (1.09%)

Updated Nov 3, 2017 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Nabriva's Lefamulin Positive in Pivotal Study, Stock Surges

Nabriva Therapeutics' (NBRV) lefamulin shows non-inferiority to Avelox in a phase III study on community-acquired bacterial pneumonia patients.

    Becton, Dickinson (BDX) Q1 Earnings: What's in the Cards?

    Becton, Dickinson and Company (BDX) is set to report first-quarter fiscal 2017 earnings results on Feb 2.

      Will PerkinElmer (PKI) Disappoint this Earnings Season?

      PerkinElmer Inc. (PKI) is expected to report fourth-quarter 2016 results on Feb 2, 2017.

        Will Baxter International (BAX) Disappoint in Q4 Earnings?

        Baxter International Inc. (BAX) is scheduled to report fourth-quarter 2016 earnings on Feb 1, before the opening bell.

          Henry Schein (HSIC) Q4 Earnings: Disappointment in Store?

          Henry Schein, Inc. (HSIC) is expected to report fourth-quarter 2016 financial numbers on Feb 8, before the opening bell.

            The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

            The Zacks Analyst Blog Highlights: RedHill Biopharma, Cempra, Vertex Pharmaceuticals, Acorda Therapeutics and Kite Pharma

              AmerisourceBergen (ABC) Q1 Earnings: Will It Disappoint?

              AmerisourceBergen Corp. (ABC) is set to report first-quarter fiscal 2017 results on Jan 31, before the opening bell.

                Cempra (CEMP): An Off-the-Radar Potential Winner

                Cempra, Inc. (CEMP). This Medical stock has actually seen estimates rise over the past month

                  C.R. Bard (BCR) to Report Q4 Earnings: A Surprise in Store?

                  Delving deeper into the fundamentals of C.R. Bard (BCR), let's see how things are shaping up prior to this quarter.

                    Is a Surprise in Store for Hologic (HOLX) in Q1 Earnings?

                    Hologic Inc. (HOLX) is slated to report first-quarter fiscal 2017 financial results on Feb 1, after the closing bell.

                      Myriad Genetics (MYGN) Q2 Earnings: What's in the Cards?

                      Myriad Genetics, Inc.(MYGN) is expected to report second-quarter fiscal 2017 results on Feb 7, after the closing bell.

                        IDEXX Laboratories (IDXX) Q4 Earnings: What's in Store?

                        IDEXX Laboratories, Inc. (IDXX) is slated to report fourth-quarter 2016 results on Feb 2, before the opening bell.

                          Will Boston Scientific (BSX) Pull a Surprise in Q4 Earnings?

                          Boston Scientific Corporation (BSX) is scheduled to report fourth-quarter and full-year 2016 results before the opening bell on Feb 2.

                            Edward Lifesciences (EW): What's in Store in Q4 Earnings?

                            Edward Lifesciences Corp. (EW) is scheduled to report fourth-quarter and full-year 2016 earnings results after market close on Feb 1, 2017.

                              Illumina (ILMN) Q4 Earnings: A Beat in Store for the Stock?

                              We expect Illumina Inc (ILMN) to beat expectations when it reports fourth-quarter 2016 results after the closing bell on Jan 31.

                                Is the Options Market Predicting a Spike in Cempra (CEMP) Stock?

                                Investors in Cempra, Inc. (CEMP) need to pay close attention to the stock based on moves in the options market lately.

                                  Cempra (CEMP) Worth a Look: Stock Jumps 7.7% in Session

                                  Cempra, Inc. (CEMP) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

                                    Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate

                                    Cempra (CEMP) announced that it received a CRL from the FDA relating to its new drug applications for oral and intravenous formulation of candidate solithromycin.

                                      Supriyo Bose headshot

                                      Why These 3 Healthcare Stocks Lost Half Their Value in November

                                      As the equity market braced itself for the Trump era, some healthcare stocks felt the tremors of his ensuing policy reforms and declined significantly in November.